Patent application number | Description | Published |
20090130086 | FXIII Variants with Improved Properties - The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed. | 05-21-2009 |
20130040888 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 02-14-2013 |
20130183280 | STABILIZED FACTOR VIII VARIANTS - The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules. | 07-18-2013 |
20140018297 | COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA - The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound. | 01-16-2014 |
20150045303 | Pharmaceutical Composition Suitable for Treatment of Haemophilia - The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia. | 02-12-2015 |
20150080309 | Compounds Suitable for Treatment of Haemophilia - The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases. | 03-19-2015 |
20150376262 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 12-31-2015 |
20160002314 | FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE - The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake. | 01-07-2016 |